EXPERIENCE OF USING PALBOCICLIB, RIBOCICLIB AND ABEMACICLIB IN A TERTIARY HOSPITAL
4CPS-139
VORICONAZOLE SERUM CONCENTRATIONS MONITORING
4CPS-138
CEFIDEROCOL: EFFECTIVENESS AND MORTALITY OF MULTIDRUG-RESISTANT BACTERIA INFECTIONS, A RETROSPECTIVE OVERVIEW.
4CPS-137
CEFIDEROCOL: UTILIZATION PROFILE IN THE TREATMENT OF MULTIDRUG-RESISTANT BACTERIA, A RETROSPECTIVE OVERVIEW.
4CPS-136
ANALYSIS OF THE SITUATION OF PHARMACEUTICAL CARE FOR PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES BEFORE AND AFTER THE COVID-19 PANDEMIC
4CPS-135
EVALUATION AND MANAGEMENT OF CONSTIPATION IN THE CRITICALLY ILL PATIENT
4CPS-134
REAL WORLD EVIDENCE OF CEFIDEROCOL IN CLINICAL PRACTICE
4CPS-133
EFFECTIVENESS AND SAFETY OF ANTI IL-5 DRUGS BENRALIZUMAB AND MEPOLIZUMAB IN SEVERE UNCONTROLLED EOSINOPHILIC ASTHMA PATIENTS
4CPS-132
RIBOCICLIB IN METASTASIC BREAST CANCER TREATMENT: FRECUENCY AND ANALYSIS OF DIFFERENTS ADVERSE EFFECTS WHICH REQUIRED INTERVENTION
4CPS-131
UTILIZATION AND SAFETY PROFILE OF UPADACITINIB IN A TERTIARY HOSPITAL
4CPS-130
RISK OF HYPOKALAEMIA IN HOSPITALIZED PATIENTS ASSOCIATED WITH THE COMBINATION OF DIURETICS
4CPS-129
EVALUATION OF THE BENEFIT OF CAROB FLOUR ON NINTEDANIB DIARRHEA IN THE TREATMENT OF DIFFUSE INTERSTITIAL LUNG DISEASE
4CPS-128
POTENTIAL DRUG-DRUG INTERACTIONS IN HYPERTENSIVE PATIENTS
4CPS-127
PERSISTENCE OF BIOLOGICAL DISEASE-MODIFYING DRUGS AND PHOSPHODIESTERASE-4- INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITHIS
4CPS-126
ADHERENCE, PERSISTENCE, AND SWITCHING MEDICATION IN PATIENTS WITH MULTIPLE SCLEROSIS INITIATING ORAL DISEASE MODIFYING THERAPIES: A RETROSPECTIVE REAL-WORLD STUDY
